Cargando…

Comparative genomic analysis of primary tumors and metastases in breast cancer

Personalized medicine uses genomic information for selecting therapy in patients with metastatic cancer. An issue is the optimal tissue source (primary tumor or metastasis) for testing. We compared the DNA copy number and mutational profiles of primary breast cancers and paired metastases from 23 pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertucci, François, Finetti, Pascal, Guille, Arnaud, Adélaïde, José, Garnier, Séverine, Carbuccia, Nadine, Monneur, Audrey, Charafe-Jauffret, Emmanuelle, Goncalves, Anthony, Viens, Patrice, Birnbaum, Daniel, Chaffanet, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053643/ https://www.ncbi.nlm.nih.gov/pubmed/27028851 http://dx.doi.org/10.18632/oncotarget.8349

Ejemplares similares

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases
por: Tyran, Marguerite, et al.
Publicado: (2019)

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
por: Bertucci, François, et al.
Publicado: (2020)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling
por: Cornen, Stéphanie, et al.
Publicado: (2014)

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
por: Gonçalves, Anthony, et al.
Publicado: (2016)

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes
por: Bekhouche, Ismahane, et al.
Publicado: (2011)

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
por: Bertucci, François, et al.
Publicado: (2021)

8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer
por: Bertucci, François, et al.
Publicado: (2012)

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial
por: Sabatier, Renaud, et al.
Publicado: (2022)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2011)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study
por: Sabatier, Renaud, et al.
Publicado: (2022)

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
por: Billon, Emilien, et al.
Publicado: (2022)

MARCKS protein overexpression in inflammatory breast cancer
por: Manai, Maroua, et al.
Publicado: (2016)

Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value
por: Doghri, Raoudha, et al.
Publicado: (2017)

ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines
por: Udu-Ituma, Sandra, et al.
Publicado: (2023)

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
por: Letessier, Anne, et al.
Publicado: (2006)

Loss, mutation and deregulation of L3MBTL4 in breast cancers
por: Addou-Klouche, Lynda, et al.
Publicado: (2010)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
por: Guerin, Mathilde, et al.
Publicado: (2018)

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
por: Sircoulomb, Fabrice, et al.
Publicado: (2011)

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
por: Sircoulomb, Fabrice, et al.
Publicado: (2011)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

Signaling pathway switch in breast cancer
por: Guille, Arnaud, et al.
Publicado: (2013)

Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy
por: Neron, Mathias, et al.
Publicado: (2022)

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification
por: Cervera, N, et al.
Publicado: (2017)

BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
por: Azzoni, Violette, et al.
Publicado: (2022)

Molecular characterization of breast cell lines: a tool for breast cancer studies
por: Charafe-Jauffret, E, et al.
Publicado: (2005)

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
por: Ben Hamida, Azza, et al.
Publicado: (2008)

Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2–JNK signalling in breast cancer
por: Puvirajesinghe, Tania M., et al.
Publicado: (2016)

Integrated Genomic Analysis of Breast Cancers
por: Addou-Klouche, L, et al.
Publicado: (2012)

Nectin-4 is a new histological and serological tumor associated marker for breast cancer
por: Fabre-Lafay, Stéphanie, et al.
Publicado: (2007)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
por: Collette, Y, et al.
Publicado: (2015)

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
por: Gilabert, Marine, et al.
Publicado: (2014)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Goncalves, Anthony, et al.
Publicado: (2021)

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fp2jsg2oath3ab2t7j7bmnmd7d